Please login to the form below

Not currently logged in
Email:
Password:

Vectura to collaborate on COPD therapy

Respiratory disease specialist Vectura has said it is to collaborate with a 'leading pharmaceutical company' to develop and market new combination asthma/COPD therapy in the US

Respiratory disease specialist Vectura has said it is to collaborate with a 'leading pharmaceutical company' to develop and market a new combination asthma/COPD therapy in the US.

The unnamed company will replace Novartis' generics arm Sandoz in the deal to make use of Vectura's proprietary technology to bring investigational drug VR315 to the US market. Sandoz is continuing to develop for Europe.

Vectura will receive an initial payment of $10m, with $35m available in milestone payments. Royalties will also be available.

The company's partner will be responsible for the commercialisation and manufacture of the product together with clinical development.

Dr Chris Blackwell, CEO of Vectura, commented: "This is a major endorsement of the potential value of this product, Vectura's technology and product development expertise."

4th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics